Pulmonary Hypertension: The Breathlessness That Isn't Just Being Out of Shape

Cardiology · 4 · March 13, 2026

You're 42. Reasonably active. But lately, climbing stairs leaves you breathless. You mention it to your doctor. "You should exercise more," they say. Two years later, you're winded walking across a parking lot. Another doctor says it's anxiety. Or deconditioning. Or asthma. Eventually — often 2-3 years after symptoms begin — someone orders the right test and finds pulmonary hypertension. This delay is tragically common.

What Pulmonary Hypertension Is

Normal blood pressure in the lungs is about 14 mmHg at rest. Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure above 20 mmHg, measured by right heart catheterization. The elevated pressure makes the right ventricle work harder to pump blood through the lungs. Over time, the right ventricle thickens, dilates, and eventually fails.

The WHO classifies PH into five groups. Group 1 — pulmonary arterial hypertension (PAH) — involves intrinsic disease of the pulmonary arteries themselves. It's the rarest form (about 15-50 per million) but the most studied and most treatable with targeted therapies. Group 2 (left heart disease) and Group 3 (lung disease/hypoxia) are far more common and are treated by managing the underlying condition.

Why It Takes So Long to Diagnose

The earliest symptom is exertional dyspnea — shortness of breath during activity. It's nonspecific. Every out-of-shape 40-year-old has it. Doctors reasonably start with common explanations: anemia, asthma, deconditioning, anxiety. Only when symptoms progress — syncope (fainting) during exertion, chest pressure, peripheral edema, exercise intolerance disproportionate to fitness level — does the workup expand.

A 2023 study in European Respiratory Journal found that the average time from symptom onset to PH diagnosis was 2.8 years. Patients saw an average of 3.7 physicians before getting the correct diagnosis. Each year of delay correlates with worse functional class at diagnosis and shorter survival.

The echocardiogram is the screening tool. It estimates pulmonary artery systolic pressure (PASP) noninvasively. A PASP above 35-40 mmHg on echo raises suspicion. But the definitive diagnosis requires right heart catheterization — the gold standard. If your doctor suspects PH, don't accept an echo alone as the final answer; push for catheterization.

Treatment: More Options Than Ever

For Group 1 PAH, multiple drug classes now exist. Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) block a potent vasoconstrictor. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) promote vasodilation — yes, the same drugs used for erectile dysfunction, repurposed for the lungs. Prostacyclin pathway agents (epoprostenol, treprostinil, selexipag) are the most potent vasodilators and are used in advanced disease.

The GRIPHON trial showed selexipag reduced disease progression by 40% in PAH. The AMBITION trial demonstrated that upfront combination therapy (ambrisentan + tadalafil) reduced clinical failure events by 50% compared to monotherapy. The message: early, aggressive combination therapy produces the best outcomes. Don't accept a single drug if your hemodynamics warrant more.

Sotatercept (Winrevair), approved by the FDA in 2024, represents a new mechanism — it rebalances the TGF-beta signaling pathway that drives pulmonary vascular remodeling. The STELLAR trial showed sotatercept improved 6-minute walk distance by 40 meters and reduced pulmonary vascular resistance by 36% when added to background therapy. It's the most significant advance in PAH treatment in over a decade.

Living With Pulmonary Hypertension

PH requires specialized care. The Pulmonary Hypertension Association maintains a list of accredited PH care centers with expertise in diagnosis, treatment, and long-term management. Patients should avoid pregnancy (maternal mortality in PAH is 17-33%), high altitude (above 5,000 feet can worsen hypoxia), and heavy isometric exercise. Moderate aerobic exercise, however, is beneficial — a 2024 randomized trial in The Lancet Respiratory Medicine showed supervised exercise training improved 6-minute walk distance and quality of life in PH patients.

Key Takeaways

- Pulmonary hypertension takes an average of 2.8 years to diagnose — unexplained breathlessness disproportionate to fitness should raise suspicion

- Echocardiogram screens for PH, but right heart catheterization is required for definitive diagnosis

- Upfront combination therapy reduces clinical failure by 50% compared to single-drug treatment (AMBITION trial)

- Sotatercept (Winrevair), approved in 2024, is the most significant new PAH treatment in over a decade

- Specialized PH care centers improve outcomes — find an accredited center through the PH Association

Concerned about unexplained breathlessness? Start with our symptom-based cardiac risk assessment to determine if further evaluation is warranted.